Literature DB >> 15844713

MELD score does not discriminate against patients with hepatic encephalopathy.

Jasmohan S Bajaj1, Kia Saeian.   

Abstract

Hepatic encephalopathy (HE) is a significant complication of cirrhosis and part of the CTP score. The UNOS database was queried for listings from February 2001 to February 2002 (CTP era) and February 2002 to February 2003 (MELD era). HE at listing, Grade III/IV HE at transplant, and 12-month posttransplant survival were compared. HE rate at listing was similar, whereas Grade III/IV HE at time of transplant was significantly lower in the MELD era. Waiting periods were shorter in the MELD era. Twelve-month posttransplant survival was lower in all patients with HE at listing (P < 0.0001) and for patients with Grade III/IV HE at transplant (P < 0.0001) in both eras. No significant change in posttransplant survival of HE patients was observed after MELD implementation. We conclude that (1) HE patients have worse posttransplant survival even after MELD; (2) MELD allows more rapid transplantation; and (3) rates of HE at listing have not changed since MELD implementation; however, rates of Grade III/IV HE at transplant have decreased.

Entities:  

Mesh:

Year:  2005        PMID: 15844713     DOI: 10.1007/s10620-005-2568-y

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  10 in total

1.  Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo End-stage Liver Disease.

Authors:  L M Forman; M R Lucey
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

2.  Prognostic significance of hepatic encephalopathy in patients with cirrhosis.

Authors:  J Bustamante; A Rimola; P J Ventura; M Navasa; I Cirera; V Reggiardo; J Rodés
Journal:  J Hepatol       Date:  1999-05       Impact factor: 25.083

3.  Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests.

Authors:  P Amodio; F Del Piccolo; P Marchetti; P Angeli; R Iemmolo; L Caregaro; C Merkel; G Gerunda; A Gatta
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

Review 4.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

5.  MELD and other factors associated with survival after liver transplantation.

Authors:  K V Narayanan Menon; Scott L Nyberg; William S Harmsen; Nelson F DeSouza; Charles B Rosen; Ruud A F Krom; Russell H Wiesner
Journal:  Am J Transplant       Date:  2004-05       Impact factor: 8.086

Review 6.  Fulminant hepatic failure: summary of a workshop.

Authors:  J H Hoofnagle; R L Carithers; C Shapiro; N Ascher
Journal:  Hepatology       Date:  1995-01       Impact factor: 17.425

Review 7.  Improving liver allocation: MELD and PELD.

Authors:  Richard B Freeman; Russell H Wiesner; John P Roberts; Suzanne McDiarmid; Dawn M Dykstra; Robert M Merion
Journal:  Am J Transplant       Date:  2004       Impact factor: 8.086

8.  Results of the first year of the new liver allocation plan.

Authors:  Richard B Freeman; Russell H Wiesner; Erick Edwards; Ann Harper; Robert Merion; Robert Wolfe
Journal:  Liver Transpl       Date:  2004-01       Impact factor: 5.799

9.  Relationship of the model for end-stage liver disease (MELD) scale to hepatic encephalopathy, as defined by electroencephalography and neuropsychometric testing, and ascites.

Authors:  Hwan Y Yoo; David Edwin; Paul J Thuluvath
Journal:  Am J Gastroenterol       Date:  2003-06       Impact factor: 10.864

10.  Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease.

Authors:  Adnan Said; John Williams; Jeremy Holden; Patrick Remington; Ronald Gangnon; Alexandru Musat; Michael R Lucey
Journal:  J Hepatol       Date:  2004-06       Impact factor: 25.083

  10 in total
  1 in total

1.  Model for End-Stage Liver Disease and liver cirrhosis-related complications.

Authors:  Luis Calzadilla Bertot; Eduardo Vilar Gomez; Linnet Alonso Almeida; Enrique Arus Soler; Luis Blanco Perez
Journal:  Hepatol Int       Date:  2012-10-10       Impact factor: 6.047

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.